Filtered By:
Condition: Thrombosis
Drug: Activase

This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 351 results found since Jan 2013.

Simultaneous thrombosis of 2 vascular territories: is thrombolytic therapy a better option?
We have read with great interest the article by Akyuz and colleagues in the American Journal of Emergency Medicine and congratulate them for their observation. Their case exemplifies the concurrent occurrence of ST-segment elevation myocardial infarction (STEMI) and posterior circulation stroke that was eventually managed with thrombolytic therapy. Simultaneous thrombosis of 2 distant vascular territories is a rare and complicated clinical scenario. In these instances, there is usually an underlying cause linking both thrombotic events rather than being a mere coincidence. We have previously described the myocardial infarc...
Source: The American Journal of Emergency Medicine - July 1, 2013 Category: Emergency Medicine Authors: Hesham R. Omar, Devanand Mangar, Enrico M. Camporesi Tags: Correspondence Source Type: research

The Elusive Golden Hour - A Multicenter Analysis of the Difficulties of Timely Intravenous Alteplase Treatment (P03.189)
CONCLUSIONS: Many factors contribute to delay in IV thrombolytic treatment in the acute stroke patient. In many patients when stabilization is needed or when the clinical presentation is confusing, it may be in the patient's best interest to delay thrombolytics until the situation is clarified. We must strive to identify causes of delay in our institutions to maintain maximum benefit of thrombolytic therapy for our patients.Disclosure: Dr. Sugg has received personal compensation for activities with Genetech as a speaker. Dr. Chaudhrey has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Ehtisham has nothing to di...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Sugg, R., Chaudhrey, B., Chen, S., Ehtisham, A., Summers, D., Rymer, M. Tags: P03 Cerebrovascular Disease III Source Type: research

Intravenous thrombolysis in CADASIL: report of two cases and a systematic review
ConclusionsAvailable data on intravenous thrombolysis in CADASIL patients are scarce but suggest that this treatment can be taken into consideration for these patients.
Source: Neurological Sciences - October 18, 2022 Category: Neurology Source Type: research

Thrombolysis Works in Lacunar Infarct, Complicating Imaging Selection
A new, exploratory analysis of the Efficacy and Safety of MRI-Based Thrombolysis in Wake-up Stroke (WAKE-UP) trial by Barow and colleagues in this issue ofJAMA Neurology provides unique and compelling data suggesting that thrombolysis improves clinical outcomes after acute lacunar infarction. The European Union –commissioned, 500-patient, randomized, double-blind, placebo-controlled WAKE-UP trial of alteplase captured the magnetic resonance imaging (MRI) and magnetic resonance angiography of patients with acute ischemic stroke prior to thrombolysis. This allowed categorization of infarcts as lacunar vs n onlacunar, using...
Source: JAMA Neurology - March 25, 2019 Category: Neurology Source Type: research

Correspondence Alteplase for ischaemic stroke—responses
In his Correspondence Roger Shinton raises concerns about the benefits of alteplase to treat acute ischaemic stroke. He refers to the Cochrane review of thrombolysis in acute ischaemic stroke, published in 2009, with data for 3977 patients treated with alteplase in randomised controlled trials (RCTs). Since then, the Third International Stroke Trial (IST-3) and an updated systematic review of all alteplase trials (7012 patients) have been published, and a complete update of all RCTs of all thrombolytic agents in acute ischaemic stroke (10 187 patients) in the Cochrane Database of Systematic Reviews has been very recently published.
Source: LANCET - August 23, 2014 Category: Journals (General) Authors: Joanna M Wardlaw, Veronica Murray, Eivind Berge, Gregory J Del Zoppo Tags: Correspondence Source Type: research

Urticarial allergic reaction to alteplase: A case report (P6.243)
CONCLUSIONS: Physicians treating acute ischemic stroke with alteplase should be aware of this uncommon but potentially dangerous complication in the spectrum of anaphylactic reactions.Disclosure: Dr. Papolin has nothing to disclose. Dr. Mendes has nothing to disclose. Dr. Lange has nothing to disclose. Dr. Germiniani has nothing to disclose. Dr. Harger has nothing to disclose. Dr. Zetola has nothing to disclose. Dr. Chamma has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Papolin, L., Mendes, D., Lange, M., Germiniani, F., Harger, R., Zetola, V., Chamma, J. Tags: Cerebrovascular Disease and Interventional Neurology: Thrombolysis Complications Source Type: research

Local Experience with a new retrievable stent (ERIC) in academic Center (P5.269)
Conclusions:In this study, the use of new ERIC retrieval device was technically feasible, safe, and effective in acute ischemic stroke with large-vessel occlusionDisclosure: Dr. Alshaer has nothing to disclose. Dr. Alturkustani has nothing to disclose. Dr. Khoja has nothing to disclose. Dr. Almekhlafi has nothing to disclose. Dr. Ayoub has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: AlShaer, D., Alturkustani, A., Khoja, A., Almekhlafi, M., Ayoub, O. Tags: Acute Cerebrovascular Interventional Therapies Source Type: research

Risk Factors for Early Intracerebral Hemorrhage after Intravenous Thrombolysis with Alteplase.
CONCLUSIONS: Prior stroke and atrial fibrillation are independent risk factors for early ICHs (within 12 h) after intravenous thrombolysis with alteplase. PMID: 32115471 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - March 4, 2020 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Thrombolysis for Central Retinal Artery Occlusion in 2020: Time Is Vision!
Conclusions: In 2020, nonarteritic CRAO patients should theoretically receive the same thrombolytic therapies, in the same time window, as patients with acute cerebral ischemia. Eye stroke and teleeye stroke code encounters must include an expert ophthalmologic evaluation to confirm the correct diagnosis and to evaluate for ocular signs that may help guide IV tPA administration or IA management. Future research should focus on developing feasible retinal penumbra imaging studies that, similar to cerebral tissue viability or perfusion imaging, can be incorporated into the thrombolysis decision-making algorithm.
Source: Journal of Neuro-Ophthalmology - August 25, 2020 Category: Opthalmology Tags: Disease of the Year: Cerebrovascular Disorders Source Type: research

Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?
AbstractPurpose of reviewAlteplase has been the thrombolytic of choice for acute ischaemic stroke for more than two decades. A thrombolytic which is easier to administer and with improved or comparable safety and efficacy is desirable. Tenecteplase has emerged as a potential successor, and its off-license use in acute ischaemic stroke has increased in recent years. We aimed to examine the evidence base for each drug and discuss their use in varying patient populations in acute ischaemic stroke.Recent findingsSeveral trials comparing tenecteplase and alteplase have reported very recently with the results of the ACT trial st...
Source: Current Treatment Options in Neurology - July 30, 2022 Category: Neurology Source Type: research

Evolving Thrombolytics: from Alteplase to Tenecteplase
AbstractAlteplase has been the primary thrombolytic used in the treatment of acute ischemic stroke since thrombolysis was first established as an effective treatment of acute ischemic stroke in 1995. Tenecteplase, a genetically modified tissue plasminogen activator, has gained attention as an attractive alternative to alteplase given its practical workflow advantages and possible superior efficacy in large vessel recanalization. As more data is analyzed both from randomized trials and non-randomized patient registries, there is mounting support that tenecteplase appears to be at least equally, if not more, safe and potenti...
Source: Neurotherapeutics - June 5, 2023 Category: Neurology Source Type: research

Analysis of related factors of orolingual angioedema after rt-PA intravenous thrombolytic therapy.
CONCLUSIONS: Orolingual angioedema is a rare complication that occurs after rt-PA intravenous thrombolytic therapy; when serious, it may endanger a patient's life. If patients take an oral hypotension such as ACEI drugs before the onset of OA, they have a history of allergies, or the lesion is an infraction in the dominated area of the middle cerebral artery, the risk of OA after rt-PA intravenous thrombolytic therapy will be increased. The prevalence of OA should be monitored during the rt-PA intravenous thrombolytic therapy process; timely detection and early intervention should be conducted, which can avoid serious adve...
Source: European Review for Medical and Pharmacological Sciences - March 24, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Impact of intravenous alteplase on sub-angiographic emboli in high-resolution diffusion-weighted imaging following successful thrombectomy
ConclusionsIntravenous alteplase neither affects the number nor volume of sub-angiographic DWI-PE after successful endovascular reperfusion. In the light of currently running randomized trials, further studies are warranted to validate these findings.Key Points• Thrombus microfragmentation during endovascular stroke treatment may cause peripheral emboli that are only detectable on diffusion-weighted imaging and may directly compromise treatment effects.• In this prospective study, the application of intravenous alteplase did not influence the occurrence of peripheral emboli detected on high-resolution diffusion-weighte...
Source: European Radiology - May 8, 2021 Category: Radiology Source Type: research

Efficacy and safety of alteplase on treatment of acute single small subcortical infarction
CONCLUSION: Patients with SSSI in the anterior circulation are more likely to achieve 3 months favorable outcomes than those who were treated with standard medical care, however treatment with alteplase may not prevent occurrence of END.PMID:36043775 | DOI:10.2174/1567202619666220829111211
Source: Current Neurovascular Research - August 31, 2022 Category: Neurology Authors: Kilanga Marcelinus Hongbing Liu Ke Zhang Ce Zong Hongxun Yang Yuan Gao Bo Song Yuming Xu Source Type: research